OPKO Health, Inc. (NASDAQ:OPK - Get Free Report)'s share price shot up 5% on Wednesday . The company traded as high as $1.58 and last traded at $1.57. 1,479,272 shares were traded during trading, a decline of 80% from the average session volume of 7,553,453 shares. The stock had previously closed at $1.49.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on OPK shares. StockNews.com upgraded OPKO Health to a "sell" rating in a report on Saturday, July 27th. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Thursday, September 26th. Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, September 20th. Finally, Piper Sandler reissued an "overweight" rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.
Check Out Our Latest Analysis on OPK
OPKO Health Stock Performance
The business has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.36. The company has a quick ratio of 1.36, a current ratio of 1.63 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -4.34 and a beta of 1.64.
OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The company had revenue of $182.20 million during the quarter, compared to analysts' expectations of $184.70 million. During the same period last year, the business posted ($0.03) earnings per share. The firm's revenue was down 31.3% compared to the same quarter last year. As a group, sell-side analysts forecast that OPKO Health, Inc. will post -0.29 earnings per share for the current year.
Insider Buying and Selling
In related news, major shareholder Opko Health, Inc. sold 50,000 shares of the company's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $34.49, for a total value of $1,724,500.00. Following the transaction, the insider now directly owns 2,646,972 shares of the company's stock, valued at approximately $91,294,064.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 672,562 shares of company stock worth $22,145,099 in the last three months. Corporate insiders own 47.26% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. CIBC Asset Management Inc grew its stake in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 8,978 shares during the period. Virtu Financial LLC purchased a new position in OPKO Health in the first quarter valued at $26,000. SlateStone Wealth LLC acquired a new position in shares of OPKO Health in the first quarter worth about $31,000. Moseley Investment Management Inc. purchased a new stake in shares of OPKO Health during the 1st quarter worth about $41,000. Finally, Algert Global LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 64.63% of the company's stock.
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
